{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:08:12Z","timestamp":1764922092399,"version":"3.46.0"},"reference-count":51,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2025,12,2]]},"DOI":"10.1080\/14740338.2025.2495178","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:22:02Z","timestamp":1746058922000},"page":"1383-1390","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)"],"prefix":"10.1080","volume":"24","author":[{"given":"Angelo","family":"Pirozzi","sequence":"first","affiliation":[{"name":"Humanitas University","place":["Milan, Italy"]},{"name":"IRCCS Humanitas Research Hospital","place":["Milan, Italy"]},{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Hoyek","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]},{"name":"Kyorin University Faculty of Medicine","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluseyi","family":"Abidoye","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[{"name":"Humanitas University","place":["Milan, Italy"]},{"name":"IRCCS Humanitas Research Hospital","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Luiz Serrano","family":"Uson Junior","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein","place":["Sao Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[{"name":"Mayo Clinic in Arizona","place":["Phoenix, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.506"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.157"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14086"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241235799"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83149-5"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-24-352"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14095"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2438"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.63417"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2017882"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01100-3"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953293"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01908-1"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2021.12.012"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.10.013"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00906-w"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103488"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2232302"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2036"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1042"},{"key":"e_1_3_3_27_1","unstructured":"WITHDRAWN: FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma. FDA; 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma"},{"key":"e_1_3_3_28_1","unstructured":"Taiho Oncology. NCCN oncology research program announces projects selected for funding to study futibatinib in tumors with aberrant FGFR expression in collaboration with taiho oncology. 2020. Available from: https:\/\/www.taihooncology.com\/us\/news\/2020-07-23-nccnorp-taiho-futibatinib\/"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060614"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46586-y"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1317"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2568"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01806-z"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.018"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1492"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.017"},{"key":"e_1_3_3_37_1","unstructured":"Personalized medicine for advanced biliary cancer patients (SAFIR-ABC10). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05615818?term=futibatinib&aggFilters=status:rec%20act&cond=biliary%20tract&rank=1"},{"key":"e_1_3_3_38_1","unstructured":"Study of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (FOENIX-CCA4). 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05727176#study-plan"},{"key":"e_1_3_3_39_1","unstructured":"Taiho Oncology I. Study of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (FOENIX-CCA4). 2023 [2024 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05727176"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122968"},{"key":"e_1_3_3_41_1","volume-title":"LYTGOBY [package insert]","author":"Taiho Oncology I","year":"2024","unstructured":"Taiho Oncology I. LYTGOBY [package insert]. Princeton (NJ): Taiho Oncology, Inc; 2024."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01157-0"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102851"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1259"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103091"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90742.2008"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00196-5"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad338"},{"key":"e_1_3_3_50_1","volume-title":"2024 ASCO Gastrointestinal Cancers Symposium","author":"Javle MM","year":"2024","unstructured":"Javle MM. Efficacy and safety results of FGFR1\u20133 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from Phase II clinical trial. 2024 ASCO Gastrointestinal Cancers Symposium; 2024 Jan 22; San Francisco."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS575"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4009"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2025.2495178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:04:20Z","timestamp":1764921860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2025.2495178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,2]]}},"alternative-id":["10.1080\/14740338.2025.2495178"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2025.2495178","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"type":"print","value":"1474-0338"},{"type":"electronic","value":"1744-764X"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}